全文获取类型
收费全文 | 34414篇 |
免费 | 2413篇 |
国内免费 | 121篇 |
专业分类
耳鼻咽喉 | 255篇 |
儿科学 | 1102篇 |
妇产科学 | 784篇 |
基础医学 | 4662篇 |
口腔科学 | 948篇 |
临床医学 | 3461篇 |
内科学 | 6620篇 |
皮肤病学 | 417篇 |
神经病学 | 3881篇 |
特种医学 | 1286篇 |
外国民族医学 | 6篇 |
外科学 | 4851篇 |
综合类 | 429篇 |
一般理论 | 52篇 |
预防医学 | 2473篇 |
眼科学 | 1187篇 |
药学 | 2435篇 |
中国医学 | 51篇 |
肿瘤学 | 2048篇 |
出版年
2022年 | 157篇 |
2021年 | 458篇 |
2020年 | 280篇 |
2019年 | 458篇 |
2018年 | 556篇 |
2017年 | 463篇 |
2016年 | 506篇 |
2015年 | 567篇 |
2014年 | 794篇 |
2013年 | 1319篇 |
2012年 | 2004篇 |
2011年 | 2204篇 |
2010年 | 1192篇 |
2009年 | 1126篇 |
2008年 | 2122篇 |
2007年 | 2385篇 |
2006年 | 2350篇 |
2005年 | 2351篇 |
2004年 | 2231篇 |
2003年 | 2212篇 |
2002年 | 2107篇 |
2001年 | 366篇 |
2000年 | 316篇 |
1999年 | 375篇 |
1998年 | 484篇 |
1997年 | 433篇 |
1996年 | 340篇 |
1995年 | 356篇 |
1994年 | 341篇 |
1993年 | 327篇 |
1992年 | 322篇 |
1991年 | 286篇 |
1990年 | 267篇 |
1989年 | 218篇 |
1988年 | 212篇 |
1987年 | 201篇 |
1986年 | 237篇 |
1985年 | 229篇 |
1984年 | 345篇 |
1983年 | 311篇 |
1982年 | 372篇 |
1981年 | 325篇 |
1980年 | 349篇 |
1979年 | 213篇 |
1978年 | 231篇 |
1977年 | 232篇 |
1976年 | 166篇 |
1975年 | 166篇 |
1974年 | 158篇 |
1973年 | 125篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
BACKGROUND: Somatosensory evoked potentials (SSEPs) have long been recognized as an excellent tool for detecting neural and vascular compromise during vascular, neurosurgical and orthopedic procedures. SSEPs have the ability to localize, central versus peripheral, the area of compromise. Many surgeons use only lower-limb SSEP monitoring when performing lumbar spinal surgery. The upper extremities are usually not monitored during such procedures, and monitoring oxygen saturation does not detect neural compromise. PURPOSE: To report that the expanded use of SSEP monitoring during surgery can be beneficial in detecting peripheral ischemia or neural compromise resulting from positioning. STUDY DESIGN: Three case reviews of orthopedic spine surgeries where SSEP monitoring provided early warnings of vascular and neural compression. METHODS: The cases review three different lumbar procedures in which evidence of peripheral ischemia and nerve compression were detected by SSEP monitoring. RESULTS: By the use of upper- and lower-extremity monitoring during lumbar procedures, early detection of ischemia and nerve compression were noted intraoperatively. These changes prompted examination of the patient and repositioning to correct the ischemia or compression. The repositioning in these cases corrected the problem, and no lasting effects were found. CONCLUSIONS: Including SSEP monitoring of the bilateral upper extremities should be considered during lumbar spinal procedures. Such monitoring can be offered for a slightly increased expense and only minimal time delay to place the additional required electrodes by the technician. As a direct result of the early warning of the SSEP monitoring, we were able to avoid potential ischemic injuries and improve patient outcomes. 相似文献
52.
Margaretha Jennerwein Ronald Gust Richard Müller Helmut Schnenberger Jürgen Engel Martin R. Berger Dietrich Schmhl Siegfried Seeber Reinhanidt Osieka Ghanem Atassi Danile Marchal-De Bock 《Archiv der Pharmazie》1989,322(2):67-73
The activity of stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine] dichloroplatinum(II)-complexes (1-PtCl2,R,S; 2-PtCl2, R,R/S,S; 3-PtCl2, R,R; 4-PtCl2, S,S) on several tumor models (MDA-MB 231 breast cancer cell line; P 388 leukemia, mouse; L 1210 leukemia, mouse; L 5222 leukemia, rat; Ehrlich ascites tumor, mouse--wildtype; cisplatin-, etoposide-, cyclophosphamide-, and daunomycin-resistant, resp.) is described. For comparison the analogous [1,2-bis(4-hydroxyphenyl)ethylendiamine]dichloroplatinum (II)-complexes (5-PtCl2, R, S; 6-PtCl2, R,R/S,S; 7-PtCl2, R,R; 8-PtCl2, S,S) and cisplatin are used. 1-PtCl2 to 4-PtCl2 (OH in 3,3'-positions) show their maximum antitumor effect at lower doses than 5-PtCl2 to 8-PtCl2 (OH in 4,4'-positions). 2-PtCl2 and 6-PtCl2 (R,R/S,S) are more active than 1-PtCl2 and 5-PtCl2 (R,S). 4-PtCl2 and 8-PtCl2 (S,S) are superior to 3-PtCl2 and 7-PtCl2 (R,R). On the L 5222 leukemia 2-PtCl2 (R,R/S,S), 4-PtCl2 (S,S) and 8-PtCl2 (S,S) markedly surpass cisplatin. Strong effects are produced by 2-PtCl2 to 4-PtCl2 on the Ehrlich ascites tumor (wildtype, cisplatin-, etoposide-, cyclophosphamide-, and daunomycin-resistant, resp.). The combination of 4-PtCl2 with cisplatin results in a weakly synergistic effect. 相似文献
53.
54.
55.
56.
Ronald B. George Abigail H. Melnick Erin C. Rose Ashraf S. Habib 《Journal canadien d'anesthésie》2007,54(3):218-222
PURPOSE: To report the use of regional anesthesia and iv nitroglycerin to provide anesthesia and uterine relaxation for three Cesarean deliveries (CD) involving ex utero intrapartum treatment (EXIT) of potentially life-threatening airway obstruction in the newborn. CLINICAL FEATURES: Case 1--a 36-yr-old woman at 38 weeks' gestation was scheduled for an elective CD for fetal skeletal dysplasia and micrognathia. Case 2--a 34-yr-old woman at 35 weeks gestation had a fetal ultrasound revealing fixed neck flexion and micrognathia consistent with fetal arthrogryposis. Case 3--a 27-yr-old woman presented at 38 weeks gestation for CD for severe fetal micrognathia, with mandibular growth below the fifth percentile. For each case, a combined spinal epidural anesthetic was performed with 0.75% bupivacaine, fentanyl and morphine intrathecally followed by placement of a multiorifice epidural catheter. Prior to uterine incision patients received a loading dose followed by an iv infusion of nitroglycerin. Uterine relaxation was sufficient in all cases for delivery of the fetus, and allowed for evaluation by direct laryngoscopy and intubation while maintaining fetal-placental circulation. The surgical procedures were completed without incident. CONCLUSIONS: Anesthesia and uterine relaxation for CD and EXIT procedures can be safely provided with regional anesthesia and iv nitroglycerin. 相似文献
58.
59.
Ronald Tamler Jeffrey I Mechanick 《Endocrinology & Metabolism Clinics of North America》2007,36(2):533-552
Dietary supplements and nutraceuticals are commonly used by men with erectile dysfunction, decreased libido, BPH, and concerns about developing prostate cancer. Many preparations do not contain the advertised dosages of the active ingredient or are contaminated. Dietary supplements and nutraceuticals, particularly those addressing erectile dysfunction and libido, need to undergo rigorous testing before they can be wholeheartedly recommended. 相似文献
60.
Jacobo E Mintzer Larry E Tune Christopher D Breder René Swanink Ronald N Marcus Robert D McQuade Andy Forbes 《The American journal of geriatric psychiatry》2007,15(11):918-931
OBJECTIVE: To assess the efficacy and safety of aripiprazole for psychosis associated with Alzheimer dementia (AD). METHODS: In this double-blind, multicenter study, 487 institutionalized patients with psychosis associated with AD were randomized to placebo or aripiprazole, 2, 5 or 10 mg/day. Primary efficacy assessment was the mean change from baseline to week 10 on the Neuropsychiatric Inventory-Nursing Home (NPI-NH) version Psychosis Subscale score. Secondary measures included NPI-NH Total, Clinical Global Impression-Severity of Illness (CGI-S), Brief Psychiatric Rating Scale (BPRS) Core and Total, and the Cohen-Mansfield Agitation Inventory (CMAI) scores. RESULTS: Aripiprazole 10 mg/day showed significantly greater improvements (mean change [2 x SD]) than placebo on the NPI-NH Psychosis Subscale (-6.87 [8.6] versus -5.13 [10.0]; F = 6.29, df = 1, 422, p = 0.013 by analysis of covariance [ANCOVA]); CGI-S (-0.72 [1.8] versus -0.46 [1.6]; F = 4.68, df = 1, 419, p = 0.031 [ANCOVA]); BPRS Total (-7.12 [18.4] versus -4.17 [21.6]; F = 4.72, df = 1, 399, p = 0.030 [ANCOVA]); BPRS Core (-3.07 [6.9] versus -1.74 [7.8]; F = 7.30, df = 1, 407, p = 0.007 [ANCOVA]); CMAI (-10.96 [22.6] versus -6.64 [28.6]; F = 5.23, df = 1, 410, p = 0.023 [ANCOVA]), and NPI-NH Psychosis response rate (65 versus 50%; chi(2) = 5.52, df = 1, p = 0.019 [CMH]). Aripiprazole 5 mg/day showed significant improvements versus placebo on BPRS and CMAI scores. Aripiprazole 2 mg/day was not efficacious. Cerebrovascular adverse events were reported: aripiprazole 2 mg/day, N = 1; 5 mg/day, N = 2; 10 mg/day, N = 4; placebo, N = 0. No deaths in any group (aripiprazole 2 mg/day, 3%; 5 mg/day, 2%; 10 mg/day, 7%; placebo, 3%) were considered to be treatment-related. CONCLUSION: Aripiprazole 10 mg/day was efficacious and safe for psychosis associated with AD, significantly improving psychotic symptoms, agitation, and clinical global impression. However, clinicians should be aware of the safety considerations of atypical antipsychotic uses in this population. 相似文献